Johnson & Johnson Dividend and Financial Performance Update
On April 2026, Johnson & Johnson (NYSE: JNJ) announced a 3.1% increase in its quarterly dividend, bringing it to $1.34 per share, marking the 64th consecutive annual dividend increase. This raises the annual payout to $5.36, reflecting a yield of approximately 2.1%. The company’s balance sheet remains strong, as the dividend accounts for only 46% of its expected adjusted earnings, estimated at $11.55 per share for the year.
In Q1 2026, Johnson & Johnson reported total revenue of $24.1 billion, a 9.9% increase year-over-year, driven by a surge in sales from the cancer drug Darzalex, which rose 22% to nearly $4 billion, and Tremfya, which jumped 68% to around $1.6 billion. However, the sales from Stelara, once over $10 billion annually, have declined by about 60% to $656 million, impacted by competitive biosimilars. Ongoing talc litigation poses a risk, but the company’s strong cash flow indicates it can manage this liability effectively.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
